Roth Capital Starts Cempra, Inc. (CEMP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
Cempra (CEMP) to Offer $100M in Stock
January 5, 2015 4:04 PM ESTCempra, Inc. (Nasdaq: CEMP) announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to... More
Cempra (CEMP) Surges on Positive Phase 3 Results for Solitaire-Oral
January 5, 2015 7:08 AM ESTCempra (NASDAQ: CEMP) is sharply higher (+29%) in pre-open trading Monday after the company announced positive topline results from a global, pivotal Phase 3 clinical trial of solithromycin oral capsules (Solitaire-Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP).
In the intent-to-treat population (ITT, all randomized patients), solithromycin met the primary objective of statistical non-inferiority (10% non-inferiority margin) of the early clinical response at 72 (-12/+36) hours after initiation of therapy compared to moxifloxacin. Solithromycin also met the secondary objectives of... More
Cempra (CEMP) PT Raised to $32 at Baird on Positive Solithromycin Data
January 5, 2015 6:27 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Cempra, Inc. (NASDAQ: CEMP) to $32.00 (from $21.00) after Solithromycin clears first phase 3 hurdle.
"We're encouraged by the top-line results posted by Cempra from its Solitaire-Oral study featuring solithromycin,"... More
